Devonian Health Group Inc. is preparing for a U.S. stock-market debut through an underwritten public offering and proposed listing on the NYSE American, marking a significant step in the Canadian biotech company’s effort to broaden its investor base. The company is offering up to 3.07 million common units at an estimated $6 to $8 range, with a midpoint of $7 implying approximately $21.5 million in gross proceeds before expenses. The offering is tied to the development of its lead drug candidate, Thykamine, rather than the $8 million fundraising target described in the Vittoria template.
Devonian’s Biopharmaceutical Strategy
Devonian Health Group is a clinical-stage pharmaceutical company focused on therapies for autoimmune and fibro-inflammatory diseases. Its development strategy is centered on Thykamine, a proprietary plant-derived therapeutic candidate being evaluated across several indications, including radiodermatitis associated with cancer treatment and mild-to-moderate atopic dermatitis in children. The company is also investigating potential applications in metabolic dysfunction-associated steatohepatitis and fibrotic diseases.
Chief Executive Officer and President Dr. André P. Boulet leads the company, while Dennis Turpin serves as Chief Financial Officer. Devonian has been shifting toward a more focused development model following the expiration of agreements associated with its Altius generic-drug business. As of April 30, 2026, the company reported approximately C$0.7 million in cash and a nine-month net loss of C$5.7 million, underscoring the capital requirements associated with advancing a clinical-stage pipeline.
IPO Terms and NYSE American Listing
Devonian has applied to list its common shares on NYSE American under the ticker DHGR and its warrants under DHGRW. The proposed offering consists of up to 3.07 million common units, with each unit containing one common share and one warrant. At the assumed $7 midpoint, gross proceeds would be approximately $21.49 million, while the implied post-offering equity value based on approximately 5.85 million shares would be about $41 million before considering potential warrant and option dilution.
ThinkEquity LLC is acting as representative of the underwriters. The offering also includes a 15% over-allotment option. The previously referenced 20% reduction in shares offered does not apply to Devonian’s current offering and should not be presented as an IPO term for the company.
Biotech Market Opportunity
The NYSE American listing could increase Devonian’s visibility among U.S. healthcare investors while providing a larger public-market financing channel for clinical development. The company’s opportunity depends heavily on the ability of Thykamine to demonstrate efficacy and safety in controlled clinical studies and ultimately obtain regulatory approvals in targeted indications.
Clinical and Financial Risks
Devonian remains a clinical-stage company, meaning its pipeline carries substantial development, regulatory and commercialization risk. The company has reported continuing losses and limited cash resources, while future clinical programs are expected to require additional financing. Competition from established anti-inflammatory therapies and other drug-development programs adds another layer of uncertainty, while a newly listed security may experience significant trading volatility.
Outlook: Clinical Milestones Will Drive Investor Interest
The proposed NYSE American market debut is primarily a financing and visibility event rather than a conventional growth-company IPO story. Investor interest is likely to center on clinical progress for Thykamine, regulatory milestones, cash deployment and the company’s ability to secure sufficient capital without excessive dilution. The pivotal question after the listing will be whether Devonian can convert its scientific and clinical development efforts into evidence capable of supporting a broader commercial opportunity.
